Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, multicenter, randomized, open-label, comparative study to evaluate the efficacy and safety of intramuscular ceftaroline [ceftaroline fosamil] versus intravenous linezolid in adult subjects with complicated skin and skin structure infections

Next Previous
Trial Profile

A phase 2, multicenter, randomized, open-label, comparative study to evaluate the efficacy and safety of intramuscular ceftaroline [ceftaroline fosamil] versus intravenous linezolid in adult subjects with complicated skin and skin structure infections

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Aztreonam; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Cerexa; Forest Laboratories

Most Recent Events

  • 30 Aug 2012 Actual end date added as reported by ClinicalTrials.gov record.
  • 08 Aug 2008 The expected completion date for this trial is now 1 Nov 2008.
  • 17 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top